insights_auto
Outlook: 38.3% bullish·8.5% bearish
Go to analysischevron_right
GSK:NYSE
GSK plc
$50.41
arrow_downward
-1.45%(-0.74) 1D
$50.30
arrow_downward
-0.22% (-0.11)bedtimeAfter hours
Closed: Nov 5, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$50.58
High
$51.43
Low
$50.26
Mkt. cap
101.05B
Avg. vol.
5.35M
Volume
0.00
Dividend
3.64%
Quarterly dividend
$0.46
Ex-dividend date
Aug 13, 2026
P/E ratio
17.52
52-wk high
$61.70
52-wk low
$45.80
EPS
$2.88
Beta
0.20
Shares outstanding
2.02B
No. of employees
67K
Open
$50.58
High
$51.43
Low
$50.26
Mkt. cap
101.05B
Avg. vol.
5.35M
Volume
0.00
Dividend
3.64%
Quarterly dividend
$0.46
Ex-dividend date
Aug 13, 2026
P/E ratio
17.52
52-wk high
$61.70
52-wk low
$45.80
EPS
$2.88
Beta
0.20
Shares outstanding
2.02B
No. of employees
67K
News stories
From web sources and news partners
JournalArta
·
1 hour ago
GSK Share Price: 1,890.0p, Up 0.00% Nov 5
Reuters
·
14 hours ago
Rezera launches US IPO as biotech listings wave continues
The Business Journals
·
14 hours ago
HP Inc. hires former GSK chief as CEO as company pivots to AI hardware
JournalArta
·
1 day ago
GSK Stock Analysis: Full Details
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitegsk.com